Baxter International Inc (BAX) concluded trading on Wednesday at a closing price of $34.09, with 5.11 million shares of worth about $174.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.33% during that period and on Wednesday the price saw a loss of about -1.22%. Currently the company’s common shares owned by public are about 510.93M shares, out of which, 507.40M shares are available for trading.
Stock saw a price change of -0.93% in past 5 days and over the past one month there was a price change of 9.26%. Year-to-date (YTD), BAX shares are showing a performance of 16.91% which decreased to -18.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $28.33 but also hit the highest price of $43.99 during that period. The average intraday trading volume for Baxter International Inc shares is 4.91 million. The stock is currently trading -2.51% below its 20-day simple moving average (SMA20), while that difference is up 4.26% for SMA50 and it goes to -0.79% lower than SMA200.
Baxter International Inc (NYSE: BAX) currently have 510.93M outstanding shares and institutions hold larger chunk of about 96.29% of that.
The stock has a current market capitalization of $17.44B and its 3Y-monthly beta is at 0.64. It has posted earnings per share of -$1.27 in the same period. It has Quick Ratio of 1.05 while making debt-to-equity ratio of 1.93. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BAX, volatility over the week remained 2.02% while standing at 2.89% over the month.
Stock’s fiscal year EPS is expected to rise by 31.77% while it is estimated to increase by 9.81% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on February 26, 2025 offering a Buy rating for the stock and assigned a target price of $42 to it. On February 20, 2025, Barclays Resumed their recommendations, while on July 15, 2024, Morgan Stanley Downgrade their ratings for the stock with a price target of $30. Stock get a Neutral rating from Goldman on May 30, 2024.
